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Editorials
Leprosy: what is being “eliminated”?
Paul E M Finea
Leprosy is a well known but poorly 
understood disease; even its sources and 
modes of infection transmission are still 
contentious issues. The World Health 
Organization has made important 
contributions to leprosy research and 
control through inclusion of leprosy in 
the multi-agency Special Programme 
for Research and Training in Tropical 
Diseases (TDR) and by leading a global 
leprosy elimination initiative.
In 1991 the World Health As-
sembly (WHA) passed a resolution to 
“eliminate leprosy as a public health 
problem” by the year 2000. The 
implications of this resolution have 
dominated discussion and activity in 
the leprosy community in the past 15 
years. A footnote to the WHA resolution 
explained that elimination was to be 
defined in this context as a reduction 
in prevalence below 1 per 10 000.
This is important. Prevalence at 
any point in time (e.g. 31 December) 
is a function of duration, as well as of 
incidence, and the primary strategy of 
the initiative has been to reduce preva-
lence by reducing treatment duration 
through the institution of short-course 
multiple-drug regimens. It was also 
hoped that use of these shorter-term 
and more-effective drug regimens would 
reduce infection transmission, and thus 
effectively reduce incidence of infec-
tion and ultimately of disease.
The programme has had a massive 
effect on reported prevalence. Accord-
ing to data submitted to WHO — the 
global figures are presented annually 
in the Weekly Epidemiological Record 
(WER), most recently in August 2006 
— the elimination target was reached 
globally (using the total human popu-
lation as a denominator) in 2000, and 
by the end of 2005 all but six countries 
reported year-end prevalence below 1 
per 10 000.
That much is a success. However, if 
one looks closely at the published data, it 
is not clear what has actually happened.
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The elimination initiative has 
encouraged some major changes. These 
include changes in case-finding policies: 
massive house-to-house surveys inevita-
bly find cases and lead to peaks of case 
detection, but many cases found early in 
a year are removed by the end of Decem-
ber, and hence not included in reported 
prevalence. There have been changes in 
classification: a new system based upon 
numbers of lesions is applied differently 
in different countries, making data in-
consistent with previous classification sys-
tems. Other changes are in registration, 
as some countries have not registered 
cases with single lesions or have required 
confirmation of all diagnoses by district 
teams, both of which practices reduce 
official prevalence. In terms of treatment, 
some countries have not followed WHO 
guidelines, instead maintaining cases on 
treatment for long periods, which inflates 
prevalence. Information on these changes 
is not available, though this information 
is essential for interpreting data from 
individual countries. These data should be 
included with the WER annual reports.
Though prevalence has come down, 
the extent to which there has been a 
reduction in incidence is less clear. Some 
analyses have suggested that little or 
no reduction has occurred as a result 
of the initiative.1 Incidence declines 
started in many countries long before 
this programme; these are attributable 
to improving socioeconomic conditions 
and to the Bacille Calmette–Guérin 
vaccine.
Interestingly, there is no evidence 
that the global initiative has led to the 
disappearance (“local eradication”) of 
infection or disease from any popula-
tion, and leprosy continues to appear 
throughout Africa, Asia and Latin 
America, southern Europe and even in 
the US states of Louisiana and Texas 
(where it may be a zoonosis associated 
with armadillos).
This persistence adds to the list of 
mysteries about this ancient disease. Per-
haps more time will be required to show 
the recent initiatives’ impact on inci-
dence. Or perhaps there is no effect, be-
cause we are failing to understand some 
important aspect of the disease’s natural 
history; there is some evidence that the 
leprosy bacillus may be maintained as a 
silent transient infection in nasal cavities 
in endemic areas.2,3 Research is needed 
to examine these questions.
It is not difficult to argue that 
the elimination concept has, in this 
instance, now served its purpose, and 
that it might even become detrimental 
to public health. The programme’s 
rhetoric has led to the impression in 
some quarters that leprosy no longer 
exists. This is wrong, but the distinction 
between eradication and elimination is 
widely misunderstood.
By encouraging repeated changes 
of definitions, ascertainment proce-
dures, and diagnostic and registration 
conventions, the initiative has in effect 
eliminated our ability to monitor and 
understand what has actually happened. 
And it has come close to eliminating 
leprosy research.4 Neither funders nor 
young researchers are attracted to an 
officially “eliminated” disease — even if 
it is still ubiquitous. The main leprosy 
journal of the past 70 years (the Intern
national Journal of Leprosy) published 
its last issue in March 2005, and there 
is now little active research on the 
disease, despite our continued ignorance 
of its natural history.
Leprosy and associated disabilities 
are not going to disappear for a very 
long time, if ever. As recognized in 
WHO’s Global Strategy 2006–2010, 
there will be continued need for leprosy 
research capability and for specialist 
clinical expertise.5 WHO should dis-
continue its rhetoric about eliminating 
leprosy, lest these essential efforts against 
the disease be eliminated as well.  O
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